Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis

Laboratory Investigation

Volumn 91, Issue 11, 2011, Pages 1605-1614

  Anttonen, Mikko ^a   Färkkilä, Anniina ^a   Tauriala, Hanna ^a   Kauppinen, Marjut ^a   MacLaughlin, David T ^b   Unkila Kallio, Leila ^a   Bützow, Ralf ^a   Heikinheimo, Markku ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALK; cancer treatment; Mullerian inhibiting substance; ovarian cancer; sex cord stromal tumor; Smad

Indexed keywords

ANTI MULLERIAN HORMONE RECEPTOR 2; MUELLERIAN INHIBITING FACTOR; SMAD1 PROTEIN; SMAD5 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL LINE; CONTROLLED STUDY; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL CULTURE;

EID: 80155151939     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.116     Document Type: Article

References (62)

1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180-1189. (Pubitemid 46594151)
2. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009;360:2719-2729.
3. Kim MS, Hur SY, Yoo NJ, et al. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol 2010;221:147-152.
4. Kim T, Sung CO, Song SY, et al. FOXL2 mutation in granulosa-cell tumours of the ovary. Histopathology 2010;56:408-410.
5. Jamieson S, Butzow R, Andersson N, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol 2010;23:1477-1485.
6. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell 2009;139:1130-1142.
7. Farkkila A, Anttonen M, Pociuviene J, et al. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol 2011;164:115-122.
8. Cronje HS, Niemand I, Bam RH, et al. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Am J Obstet Gynecol 1999;180:323-327. (Pubitemid 29093860)
9. Fujimoto T, Sakuragi N, Okuyama K, et al. Histopathological prognostic factors of adult granulosa cell tumors of the ovary. Acta Obstet Gynecol Scand 2001;80:1069-1074. (Pubitemid 33052226)
10. Munsterberg A, Lovell-Badge R. Expression of the mouse antimullerian hormone gene suggests a role in both male and female sexual differentiation. Development 1991;113:613-624.
11. Xavier F, Allard S. Anti-Mullerian hormone, beta-catenin and Mullerian duct regression. Mol Cell Endocrinol 2003;211:115-121.
12. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005;234:81-86.
13. Belville C, Jamin SP, Picard JY, et al. Role of type I receptors for anti-Mullerian hormone in the SMAT-1 Sertoli cell line. Oncogene 2005;24:4984-4992. (Pubitemid 41129102)
14. Visser JA. AMH signaling: from receptor to target gene. Mol Cell Endocrinol 2003;211:65-73. (Pubitemid 37491237)
15. Tran TT, Segev DL, Gupta V, et al. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smadindependent mechanism. Mol Endocrinol 2006;20:2382-2391. (Pubitemid 44496408)
16. Catlin EA, Tonnu VC, Ebb RG, et al. Mullerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. Endocrinology 1997;138:790-796. (Pubitemid 27110933)
17. Song JY, Chen KY, Kim SY, et al. The expression of Mullerian inhibiting substance/anti-Mullerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol 2009;34:1583-1591.
18. Salhi I, Cambon-Roques S, Lamarre I, et al. The anti-Mullerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 2004;379:785-793. (Pubitemid 38703663)
19. Bakkum-Gamez JN, Aletti G, Lewis KA, et al. Mullerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol 2008;108:141-148.
20. Masiakos PT, MacLaughlin DT, Maheswaran S, et al. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res 1999;5:3488-3499.
21. Chin TW, Parry RL, Donahoe PK. Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 1991;51:2101-2106.
22. Ha TU, Segev DL, Barbie D, et al. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 2000;275:37101-37109. (Pubitemid 32002128)
23. Wei X, Dombkowski D, Meirelles K, et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA 2010;107:18874-18879.
24. Stephen AE, Masiakos PT, Segev DL, et al. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. Proc Natl Acad Sci USA 2001;98:3214-3219. (Pubitemid 32220825)
25. Stephen AE, Pearsall LA, Christian BP, et al. Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 2002;8:2640-2646. (Pubitemid 34856352)
26. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, et al. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 2006;12:1593-1598.
27. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, et al. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci USA 2006;103:17426-17431. (Pubitemid 44788985)
28. Rey R, Sabourin JC, Venara M, et al. Anti-Mullerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol 2000;31:1202-1208.
29. Anttonen M, Unkila-Kallio L, Leminen A, et al. High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab 2005;90:6529-6535. (Pubitemid 41759309)
30. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8: 970-982. (Pubitemid 350174642)
31. Matzuk MM, Finegold MJ, Su JG, et al. Alpha-inhibin is a tumoursuppressor gene with gonadal specificity in mice. Nature 1992; 360:313-319. (Pubitemid 23000668)
32. Li Q, Graff JM, O'Connor AE, et al. SMAD3 regulates gonadal tumorigenesis. Mol Endocrinol 2007;21:2472-2486. (Pubitemid 47529359)
33. Li Q, Kumar R, Underwood K, et al. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol Hum Reprod 2007;13:675-683. (Pubitemid 47354915)
34. Pangas SA, Li X, Umans L, et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol Cell Biol 2008;28:248-257.
35. Middlebrook BS, Eldin K, Li X, et al. Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors. Endocrinology 2009;150:5208-5217.
36. Edson MA, Nalam RL, Clementi C, et al. Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol 2010;24:1251-1266.
37. Kyronlahti A, Kauppinen M, Lind E, et al. GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer 2010;17: 709-717.
38. Kyronlahti A, Ramo M, Tamminen M, et al. GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors. Endocrinology 2008; 149:5635-5642.
39. Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-a multivariate analysis. Gynecol Oncol 2005;96:204-209. (Pubitemid 39612438)
40. Nosov V, Silva I, Tavassoli F, et al. Predictors of recurrence of ovarian granulosa cell tumors. Int J Gynecol Cancer 2009;19:628-633.
41. Ranganath R, Sridevi V, Shirley SS, et al. Clinical and pathologic prognostic factors in adult granulosa cell tumors of the ovary. Int J Gynecol Cancer 2008;18:929-933.
42. Salonen J, Butzow R, Palvimo JJ, et al. Oestrogen receptors and small nuclear ring finger protein 4 (RNF4) in malignant ovarian germ cell tumours. Mol Cell Endocrinol 2009;307:205-210.
43. Catteau-Jonard S, Jamin SP, Leclerc A, et al. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:4456-4461. (Pubitemid 352789547)
44. Reisenauer A, Eickelberg O, Wille A, et al. Increased carcinogenic potential of myeloid tumor cells induced by aberrant TGF-beta1- signaling and upregulation of cathepsin B. Biol Chem 2007;388:639-650. (Pubitemid 46883451)
45. Nishi Y, Yanase T, Mu Y, et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 2001;142:437-445. (Pubitemid 32183706)
46. Donahoe PK, Ito Y, Hendren III WH. A graded organ culture assay for the detection of Mullerian inhibiting substance. J Surg Res 1977;23:141-148. (Pubitemid 8161433)
47. MacLaughlin DT, Epstein J, Donahoe PK. Bioassay, purification, cloning, and expression of Mullerian inhibiting substance. Methods Enzymol 1991;198:358-369.
48. MacLaughlin DT, Hudson PL, Graciano AL, et al. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology 1992;131:291-296.
49. Ragin RC, Donahoe PK, Kenneally MK, et al. Human mullerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr Purif 1992;3:236-245.
50. di Clemente N, Jamin SP, Lugovskoy A, et al. Processing of anti- Mullerian hormone regulates receptor activation by a mechanism distinct from TGF-{beta}. Mol Endocrinol 2010;24:2193-2206.
51. Papakostas TD, Pieretti-Vanmarcke R, Nicolaou F, et al. Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian inhibiting substance. Protein Expr Purif 2010;70:32-38.
52. Uhlenhaut NH, Treier M. Foxl2 function in ovarian development. Mol Genet Metab 2006;88:225-234. (Pubitemid 43963439)
53. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 2004;15:122-128. (Pubitemid 38445066)
54. Schmidt M, Kammerer U, Segerer S, et al. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol 2008;139:72-78.
55. Visser JA, Olaso R, Verhoef-Post M, et al. The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol Endocrinol 2001;15:936-945. (Pubitemid 32510640)
56. Dutertre M, Gouedard L, Xavier F, et al. Ovarian granulosa cell tumors express a functional membrane receptor for anti-Mullerian hormone in transgenic mice. Endocrinology 2001;142:4040-4046. (Pubitemid 32802677)
57. Chang HL, Pahlavan N, Halpern EF, et al. Serum Mullerian inhibiting substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol 2009;114: 57-60.
58. Weenen C, Laven JS, Von Bergh AR, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10: 77-83. (Pubitemid 38196508)
59. Renlund N, Pieretti-Vanmarcke R, O'Neill FH, et al. c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology 2008;149:108-115.
60. Pepinsky RB, Sinclair LK, Chow EP, et al. Proteolytic processing of Mullerian inhibiting substance produces a transforming growth factorbeta- like fragment. J Biol Chem 1988;263:18961-18964. (Pubitemid 19016356)
61. Donahoe PK, Clarke T, Teixeira J, et al. Enhanced purification and production of Mullerian inhibiting substance for therapeutic applications. Mol Cell Endocrinol 2003;211:37-42.
62. Yuan QA, Simmons HH, Robinson MK, et al. Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol Cancer Ther 2006;5:2096-2105. (Pubitemid 44336582)